Cytokinetics Inc

KK3A

Company Profile

  • Business description

    Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

  • Contact

    350 Oyster Point Boulevard
    South San FranciscoCA94080
    USA

    T: +1 650 624-3000

    E: [email protected]

    https://www.cytokinetics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    498

Stocks News & Analysis

stocks

Is AUB an opportunity after shares plunge 17%?

After a takeover bid was withdrawn shares dropped to below the pre-bid price.
stocks

Attractive ASX listed income opportunity

A high forward distribution yield may entice income investors.
stocks

Have the 3 biggest losers of the ASX 200 fallen too far?

Finding value in some of the ASX’s worst recent performers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,877.508.50-0.10%
CAC 408,097.070.070.00%
DAX 4023,674.5285.080.36%
Dow JONES (US)47,289.33427.09-0.90%
FTSE 1009,720.9018.370.19%
HKSE26,095.0561.790.24%
NASDAQ23,275.9289.76-0.38%
Nikkei 22549,303.450.170.00%
NZX 50 Index13,502.7754.280.40%
S&P 5006,812.630.000.00%
S&P/ASX 2008,579.707.60-0.09%
SSE Composite Index3,897.7116.29-0.42%

Market Movers